{'fraction_non_alphanumeric': 0.030390738060781478, 'fraction_numerical': 0.02604920405209841, 'mean_word_length': 5.528301886792453, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Clinical relevance of the expression of the CD31 ligand for CD38 in patients with B‐cell chronic lymphocytic leukemia

CD31 (platelet endothelial cell adhesion molecule‐1 [PECAM‐1]) is the ligand for CD38, a transmembrane glycoprotein that is expressed on the surface of leukemic cells in many patients with B‐cell chronic lymphocytic leukemia (B‐CLL). In a previous study, the authors showed that CD38 expression was correlated with a poor prognosis in patients with B‐CLL. In the current study, blood samples from patients with B‐CLL were examined to identify CD31 surface marker expression, and CD31 expression was correlated with several other known prognostic variables, including CD38.